Inventor
ERTL HILDEGUND C J
US24 patents
⚠️ This page may combine multiple inventors who share the name “ERTL HILDEGUND C J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
WISTAR INST
14 patentsUS6019978AFeb 1, 2000
Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WISTAR INST125 citations99
US5698202ADec 16, 1997
Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
WISTAR INST92 citations96
US9402888B2Aug 2, 2016
Methods and compositions for treating cancer
WISTAR INST29 citations94
US6287571B1Sep 11, 2001
Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WISTAR INST23 citations92
US6210663B1Apr 3, 2001
Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
WISTAR INST38 citations92
US10328146B2Jun 25, 2019
Contructs for enhancing immune responses
WISTAR INST4 citations81
US9724406B2Aug 8, 2017
Constructs for enhancing immune responses
WISTAR INST8 citations81
US11382886B2Jul 12, 2022
Methods and compositions for treating cancer
WISTAR INST2 citations73
US11207402B2Dec 28, 2021
Constructs for enhancing immune responses
WISTAR INST3 citations70
US12582626B2Mar 24, 2026
Methods and compositions for treating cancer
WISTAR INST0 citations62
US12390525B2Aug 19, 2025
Constructs for enhancing immune responses
WISTAR INST0 citations60
US10953108B2Mar 23, 2021
Compositions and methods of replication deficient adenoviral vectors for vaccine applications
WISTAR INST1 citations60
US12485102B2Dec 2, 2025
Methods and compositions for treating cancer
WISTAR INST0 citations56
US9744224B2Aug 29, 2017
Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens
WISTAR INST1 citations52
THE WISTAR INST
6 patentsUS9624510B2Apr 18, 2017
Adenoviral vectors comprising partial deletions of E3
THE WISTAR INST6 citations81
US12544433B2Feb 10, 2026
Melanoma canine vaccine compositions and methods of use thereof
THE WISTAR INST0 citations60
US12391959B2Aug 19, 2025
Adenoviral vectors comprising partial deletions of E3
THE WISTAR INST0 citations60
US11702675B2Jul 18, 2023
Adenoviral vectors comprising partial deletions of E3
THE WISTAR INST0 citations60
US10822619B2Nov 3, 2020
Adenoviral vectors comprising partial deletions of E3
THE WISTAR INST0 citations49
US10407696B2Sep 10, 2019
Adenoviral vectors comprising partial deletions of E3
THE WISTAR INST0 citations49
VIRION THERAPEUTICS LLC
3 patentsUS12290561B2May 6, 2025
Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
VIRION THERAPEUTICS LLC2 citations68
US11291716B2Apr 5, 2022
Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
VIRION THERAPEUTICS LLC2 citations67
US11850282B2Dec 26, 2023
Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
VIRION THERAPEUTICS LLC0 citations56